Through PhilRX, patients receive PA support, free home delivery, and the lowest guaranteed price on Addyi, with eligible commercially insured patients paying as little as $20 per month.1
Prescribing Addyi is easy
1. Eligible patients only. Restrictions apply. See Terms and Conditions
Prescribing Addyi is easy
Through PhilRX, patients receive PA support, free home delivery, and the lowest guaranteed price on Addyi, with eligible commercially insured patients paying as little as $20 per month.1
1. Eligible patients only. Restrictions apply. See Terms and Conditions
How To Prescribe Addyi
Prescribe through your EMR or directly with PhilRx:
PhilRx will TEXT PATIENT with instructions. Please include patient mobile phone number on eRx.
Search “PHILRX” in the EMR’s retail pharmacy finder or search by:
| Address: | 150 E. Campus View Blvd, Suite 210, Columbus OH 43235 |
|---|---|
| Phone: | (855) 977-0975 |
| NPI: | 1487163598 |
Send an Rx via phone or fax:
| Phone: | (855) 977-0975, Option 1 |
|---|---|
| Fax: | (888) 975-0603 |
How To Prescribe Addyi
Prescribe through your EMR or directly with PhilRx:
PhilRx will TEXT PATIENT with instructions. Please include patient mobile phone number on eRx.
Search “PHILRX” in the EMR’s retail pharmacy finder or search by:
| Address: | 150 E. Campus View Blvd, Suite 210, Columbus OH 43235 |
|---|---|
| Phone: | (855) 977-0975 |
| NPI: | 1487163598 |
Send an Rx via phone or fax:
| Phone: | (855) 977-0975, Option 1 |
|---|---|
| Fax: | (888) 975-0603 |
How To Code for HSDD*
Be sure your office uses the code for ‘HSDD’.
How To Code for HSDD*
Be sure your office uses the code for ‘HSDD’.
| * |
ICD-10-CM HSDD is F52.0NOT the code for ‘low libido’ |
|---|---|
| * |
ICD-11 HSDD is HA00.2 |
*Coding is at the discretion of the HCP and does not guarantee reimbursement.
Get Started with PhilRx
Our preferred specialty pharmacy will give you and your patients a simple and easy route to getting Addyi prescribed.
Pre-Fill Made Easy
Include ICD-10 codes and chart notes in the MD Notes or Notes to Pharmacist field within your EMR. Additionally they can be faxed to (888) 975-0603 if updates are needed after the script is sent.
Review and Send Process
Look for PhilRx notification via fax/email for CoverMyMeds (CMM) key; use CMM to review the PA and select ‘Send to Plan’ button.
Contact PhilRx
Call us at (855) 977-0975
Get Started with PhilRx
Our preferred specialty pharmacy will give you and your patients a simple and easy route to getting Addyi prescribed.
-
Pre-Fill Made Easy
Include ICD-10 codes and chart notes in the MD Notes or Notes to Pharmacist field within your EMR. Additionally they can be faxed to (888) 975-0603 if updates are needed after the script is sent.
-
Review and Send Process
Look for PhilRx notification via fax/email for CoverMyMeds (CMM) key; use CMM to review the PA and select ‘Send to Plan’ button.
-
Contact PhilRx
Call us at (855) 977-0975
Prescribing Addyi
Setting Expectations
When
One 100mg tablet of Addyi should be taken every night at bedtime.
How
Experts believe that Addyi works by correcting an imbalance of neurotransmitters responsible for sexual excitement. The specific mechanism of action is not fully understood.
Results
Patients may begin to see results early but should give Addyi at least 8 weeks4 to feel the full effects. Check with your patient if her HSDD symptoms have not improved after 8 weeks.
Prescribing Addyi
Setting Expectations
When
One 100mg tablet of Addyi should be taken every night at bedtime.
How
Experts believe that Addyi works by correcting an imbalance of neurotransmitters responsible for sexual excitement. The specific mechanism of action is not fully understood.
Results
Patients may begin to see results early but should give Addyi at least 8 weeks4 to feel the full effects. Check with your patient if her HSDD symptoms have not improved after 8 weeks.
“I had one of my patients in her early 50’s – very frustrated (with her low libido) and wanted to get it back. She took Addyi for eight weeks and I had her back to the office for a recheck – she couldn’t wait to share that she was having more sexual thoughts, fantasies and desires. This gave her that catalyst to get things going again.”
Aleece Fosnight PA-C, The Fosnight Center
Contact Us
MEDICAL INFO:
844-746-5745 x 4
medicalaffairs@sproutpharma.com
Contact Us
MEDICAL INFO:
844-746-5745 x 4
medicalaffairs@sproutpharma.com
- IQVIA Monthly Total Prescriptions Volume Data Comparing Addyi vs Vyleesi in the US. April 2024–April 2026
- Ryan KL, Arbuckle-Bernstein V, Smith G, Phillips J. Let’s Talk About Sex: A Survey of Patients’ Preferences When Addressing Sexual Health Concerns in a Family Medicine Residency Program Office. PRiMER. 2018;2:23. https://doi.org/10.22454/PRiMER.2018.728252
- Stahl SM, et al. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8:15-27
- Www.medicalnewstoday.com, 30 Nov. 2022, www.medicalnewstoday.com/articles/hypoactive-sexual-desire-disorder#overview
- Gerstenberger EP, Rosen RC, Brewer JV, et al. Sexual desire and the Female Sexual Function Index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med. 2010;7(9):3096–3103.
- Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2006; 26:2, 191-208.
- Addyi Prescribing Information.
- https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
- Clayton AH, Harry AC, Yuan J, et al. Safety of flibanserin in women treated with antidepressants: A randomized, placebo-controlled study. J Sex Med 2018;15(1):43-51.
- Arnow BA, Millheiser L, Garrett A et al. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience 2009;158:484-502.
- Woodard TL, Nowak NT, Balon R et al. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Fertil Steril 2013;100:1068-1076.
- Bianchi-Demicheli F, Cojan Y, Waber L, et al. Neural basis of hypoactive sexual desire disorder in women: an event-related fmri study. J Sex Med. 2011;8:2546-2559.
- Holstege G. How the emotional motor system controls the pelvic organs. Sex Med Rev. 2016: 4;303-328.
- Kingsberg SA. Attitudinal survey of women living with low sexual desire. J Women’s Health. 2014;23(10):817-23
- Clayton AH, Brown L, Kim NN. Evaluation of safety for flibanserin. Expert Opin Drug Saf. 2020;19(1):1-8. doi:10.1080/14740338.2020.1707804
- Goldfischer ER, Breaux J, Katz M et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): Results from a randomized withdrawal trial. J Sex Med.2011; 8:3160-3172.
- Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM; SUNFLOWER study investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012;9(12):3180-3188. doi:10.1111/j.1743-6109.2012.02942.x
- Kornstein SG, James JA, Apfel SC, et al. Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: A post hoc analysis. J Women’s Health. 2017;26(11):1161-1168.
IMPORTANT SAFETY INFORMATION
WARNING: RISK OF HYPOTENSION AND SYNCOPE IN CERTAIN SETTINGS
See full prescribing information for complete boxed warning.
- Use of ADDYI and alcohol together close in time increases this risk. Counsel patients to wait at least two hours after consuming one or two standard alcoholic drinks before taking ADDYI at bedtime or to skip their ADDYI dose if they have consumed three or more standard alcoholic drinks that evening.
- Use of ADDYI is contraindicated with strong or moderate CYP3A4 inhibitors orin patients with hepatic impairment.
Contraindications
- Moderate or strong CYP3A4 inhibitors
- Hepatic impairment
- Known hypersensitivity to ADDYI or any of its components. Reactions,including anaphylaxis, angioedema, pruritus, and urticaria have been reported.
Warnings and Precautions
- Hypotension and Syncope Due to Alcohol Interaction: See Boxed Warning.
- Hypotension and Syncope with CYP3A4 Inhibitors: See Boxed Warning and Contraindications. Concomitant use of multiple weak CYP3A4 inhibitors that may include herbal supplements (e.g., ginkgo, resveratrol) or non-prescription drugs (e.g., cimetidine) may also increase the risk.
- Central Nervous System (CNS) Depression: The risk is increased if ADDYI is taken during waking hours; with alcohol; with other CNS depressants; or with CYP3A4 inhibitors.Patients should avoid activities requiring full alertness(e.g., driving or operating machinery) until at least 6 hours after taking ADDYI and until they know how it affects them
- Hypotension and Syncope with ADDYI Alone: The risk is increased if ADDYI is taken during waking hours or if higher than the recommend dose is taken.
- Syncope and Hypotension in Patients with Hepatic Impairment: See Contraindications.
- Hypersensitivity Reactions: See Contraindications. Immediately discontinue ADDYI and initiate appropriate treatment if hypersensitivity reaction occurs.
Drug Interactions
- Oral Contraceptives and Other Weak CYP3A4 Inhibitors: Increases flibanserin exposures and incidence of adverse reactions.
- Strong CYP2C19 Inhibitors: Increases flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression.
- Digoxin: Increases digoxin concentrations, which may lead to digoxin toxicity. Increase monitoring of digoxin concentrations.
Most Common Adverse Reactions
- Most common adverse reactions (≥2% and higher than placebo) are dizziness, somnolence, nausea, fatigue, insomnia, urinary tract infection, anxiety, sinusitis, constipation and dry mouth
Please see accompanying full Prescribing Information including BOXED WARNING at ADDYI.com/PI
INDICATION
ADDYI is indicated for the treatment of women<65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD),characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: aco-existing medical or psychiatric condition; problems within the relationship; or the effects of a medication or other drug substance.
Limitations of Use:ADDYI is not for use in men or to enhance sexual performance.